Skip to main content
. 2021 Jan 27;9(1):e001647. doi: 10.1136/jitc-2020-001647

Figure 1.

Figure 1

Different oncolytic viruses exhibited different efficiency in virotherapy for B16 melanoma in mouse model. (A, B) Characterization of oncolytic virus candidates in cultured B16 cells. For infection, 1×106 cells were infected in 6-well format with TTV752-1 (1×106 PFU), LCMVARM (2×104 PFU), AdC68 (1×1010 VPs) or PR8 (5 TCID50). Supernatants or cells were collected at 12 hours, 24 hours and 36 hours after infection for viral titer determination (A); cytotoxicity was assessed at 72 hours after infection (B). Data are representative of two independent experiments. Error bars show the SEM of three biological replicates. (C) Treatment scheme. Mice were subcutaneously inoculated with 1×105 of B16 cells per mouse. When reaching about 50 mm3, tumors were directly injected with PBS (n=6), TTV752-1 (1×107 PFU, n=5), PR8 (50 TCID50, n=6), LCMVARM (2×105 PFU, n=5), ZIKAMR (1×104 PFU, n=6) or AdC68 (1×1011 VPs, n=6). (D) Kaplan-Meier survival curves of mice after virotherapy (*p<0.05, **p<0.01, log-rank test). (E) Responses of individual tumor to virotherapy in each treatment group.